Summary
Vertex Pharmaceuticals Incorporated (VRTX) has filed an 8-K report detailing the divestiture of certain assets from its wholly-owned subsidiary, PanVera LLC. On March 28, 2003, Vertex completed the sale of PanVera's proprietary reagents, probes, proteins, and certain assay capabilities to Invitrogen Corporation and also sold specific assets to Mirus Corporation. The aggregate consideration for these sales was approximately $95 million in cash, subject to adjustments, and assumption of certain liabilities by the buyers. This transaction significantly impacts Vertex's Discovery Tools and Services business segment, as PanVera was a key component of this segment. The sale does not include the instrumentation assets of this segment. The company has provided unaudited pro forma financial information, reflecting the impact of this divestiture on its balance sheet and statement of operations as if the sale had occurred on December 31, 2002, and at the beginning of the presented period, respectively. This information highlights changes in cash, assets, liabilities, revenues, and expenses.
Key Highlights
- 1Vertex sold a significant portion of its PanVera LLC subsidiary's assets (proprietary reagents, probes, proteins, assay capabilities) to Invitrogen Corporation and Mirus Corporation.
- 2The aggregate proceeds from the sale amounted to approximately $95 million in cash, with potential adjustments based on net asset value at closing.
- 3The divestiture is expected to impact Vertex's Discovery Tools and Services business segment, as PanVera was part of this segment.
- 4Vertex has provided pro forma financial statements to illustrate the financial impact of the sale, adjusting for cash proceeds and disposed assets/liabilities.
- 5The pro forma balance sheet as of December 31, 2002, shows an increase in cash and cash equivalents due to the sale proceeds.
- 6The pro forma statement of operations for the twelve months ended December 31, 2002, reflects a reduction in revenues and costs associated with the divested assets.
- 7Vertex anticipates utilizing operating losses to offset potential taxable income from the sale, thus avoiding an immediate income tax liability on the gain.